EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions

Justin Tang, Nishika Karbhari iD, Jian L Campian

Cells · 26.03.2025 · 14 (7) · 494

DOI: 10.3390/cells14070494 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.03.2025. Verfasst von Justin Tang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth, invasive infiltration into surrounding brain tissue, and resistance to conventional therapies. Despite advancements in surgery, radiotherapy, and chemotherapy, median survival remains approximately 15 months, underscoring the urgent need for innovative treatments. Key considerations informing treatment development include oncogenic genetic and epigenetic alterations that may dually serve as therapeutic targets and facilitate treatment resistance. Various immunotherapeutic strategies have been explored and continue to be refined for their anti-tumor potential. Technical aspects of drug delivery and blood–brain barrier (BBB) penetration have been addressed through novel vehicles and techniques including the incorporation of nanotechnology. Molecular profiling has emerged as an important tool to individualize treatment where applicable, and to identify patient populations with the most drug sensitivity. The goal of this review is to describe the spectrum of potential GBM therapeutic targets, and to provide an overview of key trial outcomes. Altogether, the progress of clinical and preclinical work must be critically evaluated in order to develop therapies for GBM with the strongest therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsMolecular Targeted TherapyHumansBlood-Brain BarrierAnimalsDrug Delivery SystemsImmunotherapySignal Transduction

Stichwörter der Autor:innen

CAR T cell therapyMGMT promoter methylationbiomarkersblood–brain barriercombination therapiesdrug delivery systemsepigenetic modulationgene therapyglioblastomaimmunotherapymolecular pathwaysnanotechnologyoncolytic virusestargeted therapytumor microenvironment

Autor:innen und Institutionen

  • Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada.
  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Nishika Karbhari

Zitieren

APA

Tang, J., Karbhari, N., & Campian, J. L. (2025). Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells, 14(7), 494. https://doi.org/10.3390/cells14070494

Vancouver

Tang J, Karbhari N, Campian JL. Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells. 2025;14(7):494. doi:10.3390/cells14070494

BibTeX
@article{Tang2025,
  author = {Tang, Justin and Karbhari, Nishika and Campian, Jian L},
  title = {Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {7},
  pages = {494},
  doi = {10.3390/cells14070494}
}
Kostenlos starten →